Thomas White International’s Alexion Pharmaceuticals ALXN Stock Holding History

Thomas White International’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-850	Closed	-$156K	–	324
2021 Q2	$156K	Hold	850	–	–	0.02%	274
2021 Q1	$130K	Hold	850	–	–	0.02%	279
2020 Q4	$133K	Buy	+850	New	+$109K	0.02%	274

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Thomas White International's ALXN Position: Q3 2021 in Review

Thomas White International sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 850 shares — an estimated $156K sold.

Thomas White International first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $156K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Thomas White International reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Thomas White International sold 850 Alexion Pharmaceuticals shares in Q3 2021, an estimated $156K.
Thomas White International first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Thomas White International's Alexion Pharmaceuticals position peaked at $156K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Thomas White International's 13F filing for Q3 2021, filed 12 Nov 2021.